VenoStent, Inc.’s Post

At Poseidon CRO , we're passionate about accelerating medical research to bring innovative treatments to patients in need. That's why we're thrilled to announce on this fibromyalgia awareness day , the formation of a consortium focused on advancing fibromyalgia treatment. Fibromyalgia affects millions worldwide, yet effective treatment options remain limited. By collaborating with leading rheumatology research institutions and biotech companies, we aim to expedite the development of new therapies for this complex condition. If your company is involved in fibromyalgia research or if you're a rheumatology researcher dedicated to finding solutions, we invite you to join us in this important initiative. Together, we can leverage our collective expertise, resources, and technologies to drive meaningful progress towards better outcomes for fibromyalgia patients. Please reach out via mail at : contact@poseidoncro.com Let's unite our efforts to accelerate research, foster innovation, and ultimately, transform the landscape of fibromyalgia treatment. Reach out to us today to learn more about how you can be part of this consortium and make a difference in the lives of millions. #FibromyalgiaResearch #Rheumatology #Biotech #ClinicalResearch #Collaboration #Innovation #PoseidonCRO

The current lifestyle in the Western world ensures, among other things, that the number of osteoarthritis patients continues to increase. There are already 1.5 million in the Netherlands - with all its consequences. 85% of patients experience pain and limitations in their social life every day. Orthros Medical is working on a medicine for this chronic condition - based on antibodies from llamas. CEO Robert Jan Lamers talks about this unique find and the impact it can have: "This generation of antibodies is developing very quickly. We catch that wave and surf it." Read their story: https://hubs.li/Q02mFT6H0 The Green East - Home for green development | MedTech Twente | High Tech Fund | University of Twente | Marcel Karperien | Theo Verrips | #MedTech | #hightechfund

I got turned away from entering a conference session talk.. But before going into that*, the most interesting companies that I came across last week at the London Biotechnology Show: 1. myotwin: German-based company providing tech that can support quicker translation of cardiac targeting drugs to the clinic. For early-stage biotechs working in the cardiac space, myotwin’s excitation-contraction, coupling (ECC) measurement records electrophysiology, calcium oscillation, and contractility. 2. Allegrow Biotech: Unfortunately, when I got to the booth, it was unstaffed, but its synthetic and scalable cell mimicry platform is an interesting approach to accelerate cell therapy R&D 3. NHS Institute for Innovation and Improvement: Not a company but this organization is helping med tech innovators socialize their ideas with the NHS ecosystem. No matter where you are in the development journey, if you want to commercialise in the UK, you should be registering your product and talking to these folks 4. PluumoPlus: Replacing un-environmentally friendly polystyrene with the millions of tonnes of landfill-planned feathers for insulated packaging and transport of pharmaceuticals or food is a great example of embracing *It had been a while since attending a conference and turns out there were different tiers for entry to talks vs general entry (something I had never come across having covered 10s of conferences for clients). The lady at the door wasn't a salesperson claiming "oh you can get entry at the registration stand for £xx, but its not really worth it.

🧬 In this week’s Austin Bio + Health Weekly Roundup, we have a number of launches, Austin companies teaming up, breakthroughs, acquisitions, and approvals. 🧬 🚀 Launches, Expansions, and Milestones Serial Entrepreneur Micha Y. Breakstone 🇺🇦🇮🇱, known for Chorus.AI and Neuralight, has unveiled Somite Therapeutics, a venture aimed at harnessing AI and Big Data to advance cell therapy forward. Micha, I can't wait to see what comes next. Restore Hyper Wellness announces a new personalized weight loss program, integrating patient health data, FDA approved weight loss drugs, and other therapies, with the goal to increase access to effective weight management medications and empower behavioral changes. 🤝 M&A and Partnerships NeuroX1 Inc., an AI drug discovery platform, & Everlum Bio, a personalized medicine company focused on rare and neglected neuro diseases, have joined forces in a co-development partnership, accelerating the pre-clinical development of small-molecule therapeutics. Congratulations to Maxwell Dordevic, Rick Barkley, Casey McPherson, and the rest of your teams for this promising collaboration. 🔬 Research & Medical Advancements Researchers at UT Austin and the Dell Med School, lead by Devleena Samanta and Anna Capasso, have developed new sensors based on protein-splitting enzymes, called proteases, which could be capable of detecting cancer and other diseases earlier and more precisely. 🚩 Texas Bio Triangle San Antonio-based Hera Biotech is making its first acquisition in the endometriosis diagnostic market and entering a strategic partnership with Scailyte an AI platform for the discovery of complex molecular and cellular patterns from single-cell data. Keep up the momentum Somer Baburek, MBA and crew. Plano-based AnX Robotica Corp announced FDA clearance for ProScan, a groundbreaking AI-assisted tool for small bowel video capsule endoscopy, marking an important milestone for the company. As the first Austin Bio + Health Weekly Roundup of the year, what do you think is going to be the overall theme of the sector this year? What’s Next? #AustinNext #LifeSciences #Healthcare #Biotechnology

💡 Check out the latest issue of GoingPublic Media AG magazine featuring an exclusive interview with our CEO, Dr. Daniel Vitt (in German)! 📰 ➡️ https://bit.ly/3y8yWJ9 🎤 In this insightful article, editor Stefan Riedel dives deep into our journey as a biotech company with its routes in Germany to today being a US-headquartered company listed on Nasdaq. The article outlines the clinical, regulatory and commercial potential of vidofludimus calcium in the multiple sclerosis landscape as well as upcoming milestones, including the potential approval-relevant data from our phase 2 CALLIPER trial in progressive MS, expected in April 2025. ❗Don't miss this❗ #Immunic #IMUX #Vidofludimus #ENSURE #CALLIPER #MultipleSclerosis #MS #RMS #PMS #Biotech #LifeSciences #PlattformLifeSciences #Nasdaq #NasdaqListed

🚀 News from Our Propelling Grant Program! #3 🚀 We are thrilled to announce another #winner of the #PropellingGrant – Congrats to the innovators from MirEndo Jacopo Millul, PhD & Melpomeni Fani from the University of Basel & Universitätsspital Basel (USB)! MirEndo convinced the selection committee with cutting-edge technology to diagnose endometriosis through high-precision radiopharmaceuticals and positron emission tomography scans. Some time ago, we sat down with MirEndo and asked them some questions! Read the interview here: 𝗤: 𝗖𝗮𝗻 𝘆𝗼𝘂 𝗱𝗲𝘀𝗰𝗿𝗶𝗯𝗲 𝘄𝗵𝗮𝘁 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗠𝗶𝗿𝗘𝗻𝗱𝗼 𝘄𝗮𝗻𝘁𝘀 𝘁𝗼 𝘁𝗮𝗰𝗸𝗹𝗲? A: Endometriosis affects 1 in 10 women in the world. Nevertheless, no specific diagnostic exists. For this reason, patients consult different gynaecologists during their lives, and the official diagnosis (possible only with an invasive surgical procedure) comes 7-10 years after the first symptoms occur. Altogether, this patient journey has an economic impact of about 120 billion USD/year. With MirEndo, we are aiming to shorten this journey from years to a few months, by providing a reliable and fast diagnostic and staging solution for endometriosis. 𝗤: 𝗛𝗼𝘄 𝗶𝘀 𝘁𝗵𝗲 𝗣𝗿𝗼𝗽𝗲𝗹𝗹𝗶𝗻𝗴 𝗚𝗿𝗮𝗻𝘁 𝗵𝗲𝗹𝗽𝗶𝗻𝗴 𝘆𝗼𝘂 𝘁𝗼 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗹𝗼𝗻𝗴 𝘆𝗼𝘂𝗿 𝗲𝗻𝘁𝗿𝗲𝗽𝗿𝗲𝗻𝗲𝘂𝗿𝗶𝗮𝗹 𝗷𝗼𝘂𝗿𝗻𝗲𝘆? A: The #PropellingGrant from the University of Basel will support the development of MirEndo by providing support on specific needs, such as mentoring and skill-building. The visibility offered by the Innovation Office will expand the network and allow future collaborations, helping MirEndo grow its way to become a successful start-up. . . . . Pssssss... Are you curious about the next #PropellingGrant? This is the funding instrument to help researchers with an active University of Basel affiliation turn their discoveries or ideas into a start-up. For more information, please consult our website here: https://lnkd.in/dz8fhTq We also updated the dates for 2024! Have a look: Application deadline:  ▶ 2nd of April 2024, at noon! ▶ Interviews (if selected): 19th of April 2024 ▶ Deliberation phase: until mid-May 2024 ▶ Program starts: June 2024  #AcceleratingSuccess #PropellingInnovation #Impact

SYNTHIA! Just launched online and our Kick-off meeting will take place at Medical Research Institute La Fe (IIS La Fe) on 9 & 10 September! #Syntheticdata generation framework for integrated validation of use cases and AI #healthcare applications. Help us share our posts to reach our audiences in #hematology #MMSM #DLBCL | #oncology #lungcancer - #breastcancer | #Alzheimers | #diabetes SYNTHIA is a pioneering multidisciplinary collaboration of 32 consortium partners – synthetic data generation (SDG) developers, FAIR data experts, clinical researchers, developers of therapies and data-based tools, legal experts, socio-economic analysts, regulatory, policy advocacy, and communication experts - that will provide a 360º vision on how to advance healthcare applications through synthetic data (SD) use. SYNTHIA will tackle the critical need for privacy-preserving data solutions in healthcare by developing validated tools and methods for SDG across various data types, including laboratory results, clinical notes, genomics and imaging. ___ SYNTHIA is funded by the Innovative Health Initiative (IHI)(IHI JU) under grant agreement No 101172872. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe and DNV. Supported by the European Union’s Horizon Europe research and innovation program and industry leaders such as COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and DNV, SYNTHIA is dedicated to advancing synthetic data generation for healthcare applications, ensuring that data-driven innovations can safely and effectively transform patient care. ___ #EUResearch #EUInnovation #HealthResearch #research #DataGeneration #DataScience #DataInnovation #AIinHealthcare #DigitalHealth #HealthData #PublicPrivatePartnership #PersonalizedMedicine

Khadijah Breathett: "Why diversity is needed at every level of clinical trials" Clinical trials are usually led by a single demographic: white men. Politics, sexism and structural racism can limit the opportunities for underrepresented investigators to lead clinical trials. However, all of society benefits by achieving justice, equity and diversity in clinical trials, by reducing disparities in clinical care and creating a more trustworthy healthcare system. These disparities in healthcare delivery contribute to disproportionate years of poor quality and quantity of life for underrepresented populations. Strategies are required to move from ideals to the practice of justice, equity and diversity in clinical trials, including representation at study onset and inclusion of underrepresented scientists, community leaders, community partners, and community advisory boards during the conceptualisation process. Enrollment targets for underrepresented groups should match disease prevalence or the prevalence of disease severity. Despite the amazing achievement and efforts made by the FEMaLe project, those with #endometriosis remain an underrepresented group in clinical trials. Now is the time for diversity in clinical trials accompanied by justice and equity, including benefits for underrepresented participants to boost population health. Breathett, K. Why diversity is needed at every level of clinical trials, from participants to leaders. Nat Med (2024). https://lnkd.in/dAgRb3nY. https://lnkd.in/dKya6XyB PhaseV Health studies Bogi Eliasen Trial Nation European Health and Digital Executive Agency (HaDEA) Lægemiddelstyrelsen (Danish Medicines Agency) MedWatch Innovation Fund Denmark Novartis Roche IQVIA The Synergist.org SERMAS EUPATI Gitte Kjeldsen Central Denmark EU Office (CDEU) Information Technology for Translational Medicine ECRIN (European Clinical Research Infrastructure Network) CDISC Digestive Cancers Europe European Patients' Forum Global Heart Hub Irish Platform for Patient Organisations, Science, and Industry NICE - National Institute for Health and Care Excellence National Cancer Institute (NCI) SHINE 2Europe UMC Utrecht Youth Cancer Europe AstraZeneca Bristol Myers Squibb Eli Lilly and Company Johnson & Johnson Medicines and Healthcare products Regulatory Agency Pfizer Anne Bloch Thomsen Sanofi Medicon Valley Alliance Trine Bartholdy BioInnovation Institute

Tivic Health, a bioelectronic medicine company, recently unveiled its financial results for the second quarter of 2024. The company is dedicated to advancing vagus nerve stimulation (VNS) to drive future expansion. In an exciting development, Tivic shared positive outcomes from Phase 1 trials of a novel non-invasive VNS method. This breakthrough is poised to make a significant impact on various medical conditions. Moreover, Tivic disclosed enhancements in gross margins for its ClearUP product line, a boost in revenue per marketing dollar, and a reduction in operating expenses. These achievements underscore the company's focus on streamlining its current operations. Collaborating with The Feinstein Institute of Bioelectronic Medicine, Tivic is refining its VNS program and investing in intellectual property to consolidate its position in this rapidly growing field. To delve deeper into Tivic's performance in the first half of 2024, stay tuned for the Quarterly Report on Form 10-Q, scheduled for filing on August 14, 2024. Read more about Tivic Health's Phase 1 VNS success at: https://lnkd.in/dip2pBAt Dr. Chandra Sekhar Durisety J. Dean Zikria

Scientists at the University of Alabama at Birmingham have introduced a novel 3D nanomatrix vascular sheet model for efficient atherosclerosis drug testing, as detailed in Biomaterials. This advanced model addresses the limitations of current in vitro atherosclerosis models by closely replicating the three-layer structure of vascular walls. It mimics critical atherosclerotic features, providing a more accurate platform for drug evaluation. With cardiovascular disease being a leading cause of mortality, these developments are significant. The model's scalability and efficiency make it a promising alternative to animal testing, in line with evolving regulations. This scientific advancement has potential implications beyond atherosclerosis, offering a cost-effective and efficient method for assessing therapeutic effectiveness across various health conditions. Endomimetics, LLC, recognizing the value of this technology, has licensed it, indicating potential applications in the atherosclerosis drug market. The collaboration aims to evaluate candidates for atherosclerosis treatment and possibly other related conditions. #FutureOfHealthcare #Healthcare #MedicalResearch #Atherosclerosis #CardiovascularHealth Read the full article at https://lnkd.in/eadpat3d